Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Champions Oncology's Total Stockholders Equity for the quarter that ended in Jan. 2024 was $-2.06 Mil. Champions Oncology's Total Assets for the quarter that ended in Jan. 2024 was $26.79 Mil.
Therefore, Champions Oncology's Equity to Asset Ratio for the quarter that ended in Jan. 2024 was -0.08.
The historical rank and industry rank for Champions Oncology's Equity-to-Asset or its related term are showing as below:
CSBR'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.46 Med: 0.21 Max: 0.67
Current: -0.08
During the past 13 years, the highest Equity to Asset Ratio of Champions Oncology was 0.67. The lowest was -1.46. And the median was 0.21.
CSBR's Equity-to-Asset is ranked worse than 85.16% of 1563
companies
in the Biotechnology industry
Industry Median: 0.66
vs CSBR: -0.08
Champions Oncology Equity-to-Asset Historical Data
The historical data trend for Champions Oncology's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Champions Oncology's Equity-to-Asset
For the Biotechnology subindustry, Champions Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Equity-to-Asset falls into.
Champions Oncology Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Champions Oncology's Equity to Asset Ratio for the fiscal year that ended in Apr. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (NAS:CSBR) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Champions Oncology Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Champions Oncology's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Champions Oncology (Champions Oncology) Business Description
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSBR has been successfully added to your 